Innovent Biologics (Suzhou) Co. Ltd. $1801.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS36
PHASE 3 / 2-315
RECRUITING18
READOUTS ≤12 MONTHS14
READOUT SLIPPED >6 MO21%
Delay Index: of 19 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Innovent Biologics (Suzhou) Co. Ltd. on the live radar map → 📅 $1801.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| IBI354 NCT05636215 |
P1/2 | Recruiting | Locally Advanced Unresectable or Metastatic Solid Tumors | 368 | 2025-04-30 |
| Sintilimab NCT05280626 |
P2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 100 | 2025-12-31 |
| IBI363 NCT06281678 |
P2 | Recruiting | Melanoma; Non-small Cell Lung Cancer | 178 | 2026-03-01 |
| IBI3014 NCT06974812 |
P1/2 | Recruiting | Unresectable Locally Advanced or Metastatic Solid Tumors | 250 | 2026-06-30 |
| IBI362 NCT07469800 |
P3 | Recruiting | Overweight; Obesity | 336 | 2026-08-01 |
| IBI362 NCT06937749 |
P2 | Active, not recruiting | Metabolic Dysfunction-associated Steatohepatitis (MASH) | 181 | 2026-09-23 (+5 mo) |
| IBI362 NCT06862908 |
P2 | Active, not recruiting | Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF) | 141 | 2026-09-24 |
| Tirzepatide NCT07000955 |
P1/2 | Active, not recruiting | Obesity | 98 | 2026-09-30 (-2 mo) |
| IBI363+IBI305 NCT07124793 |
P2 | Not yet recruiting | EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | 60 | 2026-09-30 |
| Pemetrexed NCT05116462 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 506 | 2026-09-30 (+37 mo) |
| IBI3003 NCT06083207 |
P1/2 | Recruiting | Multiple Myeloma | 116 | 2026-10-31 |
| Pemetrexed NCT07122687 |
P2 | Recruiting | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | 170 | 2026-11-30 |
| G-HOPE-001 NCT06238843 |
P3 | Active, not recruiting | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 464 | 2026-12-30 (+7 mo) |
| IBI363 NCT07402070 |
P2 | Not yet recruiting | Resectable Stage II-III Non-small Cell Lung Cancer | 10 | 2026-12-31 |
| IBI363 NCT06797297 |
P2 | Active, not recruiting | Melanoma | 203 | 2026-12-31 (+9 mo) |
| Dexamethasone NCT07764861 |
P2 | Not yet recruiting | Multiple Myeloma | 120 | 2026-12-31 |
| IBI362 NCT06884293 |
P3 | Active, not recruiting | Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 479 | 2026-12-31 |
| IBI311 NCT07113262 |
P3 | Recruiting | Thyroid Eye Disease | 111 | 2026-12-31 |
| Aflibercept Ophthalmic NCT05972473 |
P3 | Active, not recruiting | Neovascular Age-related Macular Degeneration | 600 | 2027-02-28 |
| IBI3002 NCT07399067 |
P2 | Recruiting | Atopic Dermatitis | 120 | 2027-03-23 |
| IBI362 NCT06931028 |
P3 | Recruiting | Sleep Apnea; Obstructive | 260 | 2027-05-07 |
| Compound Betamenth Group NCT07842497 |
P2 | Recruiting | Acute Gouty Arthritis | 132 | 2027-05-11 |
| IBI3005 NCT07612137 |
P1/2 | Not yet recruiting | Solid Tumor | 282 | 2027-06-30 |
| IBI343 NCT07066098 |
P3 | Recruiting | Pancreatic Cancer | 201 | 2027-06-30 |
| IBI362 NCT07255209 |
P3 | Recruiting | Adolescents With Obesity or Overweight With Weight-Related Comorbidities | 180 | 2027-10-31 |
| Part B -Telitacicept NCT07836660 |
P2 | Not yet recruiting | Sjögren's Disease | 198 | 2027-11-01 |
| IBI354 NCT06834672 |
P3 | Active, not recruiting | Ovarian; Primary Peritoneal | 450 | 2027-12-28 |
| IBI343,Gemcitabine, Albumin-bound Paclitaxel NCT07483554 |
P2 | Recruiting | CLDN18.2 Positive; Gastric/Gastroesophageal Junction Adenocarcinoma | 389 | 2028-03-31 |
| Sintilimab NCT05890742 |
P3 | Active, not recruiting | MSI-H | 453 | 2028-04-15 |
| Dupilumab Injection NCT07754786 |
P3 | Recruiting | Atopic Dermatitis | 520 | 2028-07-01 |
| IBI363 NCT06081920 |
P2 | Recruiting | Melanoma | 180 | 2028-10-19 (+40 mo) |
| IBI363 + bevacizumab NCT07722494 |
P3 | Recruiting | Colorectal Cancer | 550 | 2028-10-31 |
| IBI3016 NCT07352969 |
P2 | Active, not recruiting | Hypertension | 352 | 2029-03-27 |
| Pomalidomide Capsules NCT07623798 |
P3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 255 | 2029-05-31 |
| Oxaliplatin NCT07917468 |
P3 | Not yet recruiting | Locally Advanced Rectal Cancer | 500 | 2030-03-25 |
| IBI343,sintilimab,oxaliplatin,S-1 NCT07483567 |
P2 | Recruiting | CLDN18.2 Positive; Primary Gastric Adenocarcinoma | 90 | 2030-06-30 |